J. Scherrmann

发表

Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter.

A. Urtti, M. Yliperttula, A. Urtti, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A physiologically based modeling strategy during preclinical CNS drug development.

B. Walther, X. Declèves, J. Scherrmann, 2014, Molecular pharmaceutics.

Comparing translational population‐PBPK modelling of brain microdialysis with bottom‐up prediction of brain‐to‐plasma distribution in rat and human

François Bouzom, Bernard Walther, B. Walther, 2014, Biopharmaceutics & drug disposition.

Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.

M. Pocard, Y. Panis, Y. Bouhnik, 2010, Molecular pharmaceutics.

ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas

X. Declèves, J. Scherrmann, David Gomez-Zepeda, 2019, Pharmaceutics.

ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders

Marie-Anne Loriot, M. Loriot, P. Beaune, 2010, Expert opinion on drug metabolism & toxicology.

A functional in vitro model of rat blood–brain barrier for molecular analysis of efflux transporters

T. Terasaki, N. Chaverot, S. Cazaubon, 2007, Brain Research.

Puromycin‐based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood–brain barrier‐specific properties

P Couvreur, M Debray, P. Couvreur, 2005, Journal of neurochemistry.

Expression and function of multidrug resistance transporters at the blood–brain barriers

J. Scherrmann, 2005, Expert opinion on drug metabolism & toxicology.

Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

S. Cisternino, F. Roux, J. Scherrmann, 2004, Cancer research.

Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: focus on astrocytes

F. Roux, J. Scherrmann, C. Mercier, 2004, Brain Research.

Elimination of Paraquat

R. Garnier, P. Pontal, J. Scherrmann, 1987, Human toxicology.

Targeted unlabeled multiple reaction monitoring analysis of cell markers for the study of sample heterogeneity in isolated rat brain cortical microvessels

M. Picard, M. Vidal, I. Broutin, 2017, Journal of neurochemistry.

Nicotine Dependence and Its Treatment

C. Heyser, T. Robbins, P. Svenningsson, 2010 .

Methodologies to Assess Drug Permeation Through the Blood–Brain Barrier for Pharmaceutical Research

P. Carrupt, S. Martel, J. Scherrmann, 2013, Pharmaceutical Research.

Transport of Cationized Anti‐Tetanus Fab'2 Fragments Across an In Vitro Blood‐Brain Barrier Model: Involvement of the Transcytosis Pathway

L. Fenart, M. Dehouck, R. Cecchelli, 1999, Journal of neurochemistry.

Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers.

J. Oppert, J. Laplanche, T. Terasaki, 2016, Molecular pharmaceutics.

Clonidine Transport at the Mouse Blood—Brain Barrier by a New H+ Antiporter that Interacts with Addictive Drugs

M. Debray, S. Cisternino, J. Scherrmann, 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Coexistence of Passive and Proton Antiporter-Mediated Processes in Nicotine Transport at the Mouse Blood–Brain Barrier

M. Debray, S. Cisternino, J. Scherrmann, 2012, The AAPS Journal.

Microdialysis in mice for drug delivery research.

J. Scherrmann, G. Boschi, 2000, Advanced drug delivery reviews.

KCNH2 polymorphism and methadone dosage interact to enhance QT duration.

J. Lépine, J. Laplanche, V. Bloch, 2014, Drug and alcohol dependence.

Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy

G. Pasternak, A. Rees, C. Rousselle, 2003, Journal of Pharmacology and Experimental Therapeutics.

Role of ABC transporters in the chemoresistance of human gliomas.

J. Delattre, X. Declèves, J. Scherrmann, 2006, Current cancer drug targets.

Expression of drug transporters at the blood–brain barrier using an optimized isolated rat brain microvessel strategy

X. Declèves, C. Marie-Claire, F. Roux, 2007, Brain Research.

Antibody treatment of toxin poisoning--recent advances.

J. Scherrmann, 1994, Journal of toxicology. Clinical toxicology.

New approaches in antivenom therapy.

V. Choumet, C. Bon, F. Audebert, 1996, Advances in experimental medicine and biology.

Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy.

V. Choumet, C. Bon, M. Debray, 1997, The Journal of pharmacology and experimental therapeutics.

Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.

R. Gershoni-baruch, A. Chetrit, E. Niel, 2004, Seminars in arthritis and rheumatism.

Effects of Selected OATP and/or ABC Transporter Inhibitors on the Brain and Whole-Body Distribution of Glyburide

F. Dollé, H. Valette, A. Dubois, 2013, The AAPS Journal.

Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates

F. Dollé, H. Valette, M. Bottlaender, 2012, Pharmaceutical Research.

Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.

M. Plotkine, J. Scherrmann, H. Bhargava, 1995, The Journal of pharmacology and experimental therapeutics.

Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.

C. Daumas-Duport, T. Terasaki, P. Couraud, 2011, Molecular pharmaceutics.

Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.

C. Rousselle, J. Temsamani, J. Scherrmann, 2001, The Journal of pharmacology and experimental therapeutics.

Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.

M. Debray, J. Scherrmann, G. Hong, 1998, Toxicology and applied pharmacology.

Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier.

R. Shawahna, X. Declèves, J. Scherrmann, 2011, Current drug metabolism.

Analytical Control Procedures of Immunoreactivity for IgG and Fab Fragments Specific to Haptens

J. Scherrmann, M. Grandgeorge, M. Urtizberea, 1992, Pharmaceutical Research.

The effect of morbid obesity on morphine glucuronidation

J. Bouillot, C. Poitou, A. Rouquette, 2016, Pharmacological research.

Immunotoxicotherapy: present status and future trends.

J. Scherrmann, J. Bourre, M. Urtizberea, 1989, Journal of toxicology. Clinical toxicology.

Immunotoxicotherapy: Successes, disappointments and hopes

P. Taboulet, J. Scherrmann, F. Baud, 1997, Human & experimental toxicology.

Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.

M. Debray, J. Scherrmann, M. Bazin-Redureau, 1996, Toxicology and applied pharmacology.

Fab‐bound Colchicine Appears to Adopt Fab Fragment Disposition in Rats

J. Scherrmann, M. Urtizberea, A. Sabouraud, 1992, The Journal of pharmacy and pharmacology.

Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments.

J. Scherrmann, M. Grandgeorge, M. Urtizberea, 1991, Toxicology.

Specific Anti-digoxin Fab Fragments: an Available Antidote for Proscillaridin and Scilliroside Poisoning?

R. Garnier, J. Scherrmann, M. Urtizberea, 1990, Human & experimental toxicology.

Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age.

J. Scherrmann, F. Baud, N. Grene-Lerouge, 2003, British journal of clinical pharmacology.

Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies.

J. Scherrmann, M. Urtizberea, N. Terrien, 1990, Toxicology and applied pharmacology.

The effect of colchicine-specific active immunization on colchicine toxicity and disposition in the rabbit.

J. Scherrmann, M. Urtizberea, N. Terrien, 1989, Toxicology.

Reversal of murine colchicine toxicity by colchicine-specific Fab fragments.

J. Scherrmann, M. Grandgeorge, M. Urtizberea, 1991, Toxicology letters.

Time- and dose-dependent digoxin redistribution by digoxin-specific antigen binding fragments in a rat model.

J. Scherrmann, C. Renard, E. Weinling, 1999, Toxicology.

Development of a Sensitive Radioimmunoassay for Fab Fragments: Application to Fab Pharmacokinetics in Humans

J. Scherrmann, M. Urtizberea, A. Sabouraud, 1993, Pharmaceutical Research.

Colchicine-specific Fab fragments alter colchicine disposition in rabbits.

J. Scherrmann, M. Grandgeorge, M. Urtizberea, 1992, The Journal of pharmacology and experimental therapeutics.

Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes.

R. Shawahna, X. Declèves, J. Scherrmann, 2012, Current drug metabolism.

Placental Transfer of Maraviroc in an Ex Vivo Human Cotyledon Perfusion Model and Influence of ABC Transporter Expression

L. Mandelbrot, G. Peytavin, X. Declèves, 2013, Antimicrobial Agents and Chemotherapy.

Vector-mediated drug delivery to the brain

A. Rees, C. Rousselle, J. Temsamani, 2001, Expert opinion on biological therapy.

Chapter 26 – Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs

J. Scherrmann, 2008 .

Chapter 34 – Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs

J. Scherrmann, 2008 .

In Situ Transport of Vinblastine and Selected P-glycoprotein Substrates: Implications for Drug-Drug Interactions at the Mouse Blood-Brain Barrier

C. Rousselle, M. Debray, S. Cisternino, 2004, Pharmaceutical Research.

In Vivo Saturation of the Transport of Vinblastine and Colchicine by P-Glycoprotein at the Rat Blood–Brain Barrier

C. Rousselle, M. Debray, S. Cisternino, 2003, Pharmaceutical Research.

Influence of Development, HIV Infection, and Antiretroviral Therapies on the Gene Expression Profiles of ABC Transporters in Human Lymphocytes

F. Batteux, S. Chouzenoux, F. Goffinet, 2010, Journal of clinical pharmacology.

Drug Metabolism at the Blood–Brain and Blood–CSF Barriers

J. Ghersi-Egea, X. Declèves, J. Scherrmann, 2014 .

Apparent Lack of Mrp1-Mediated Efflux at the Luminal Side of Mouse Blood-Brain Barrier Endothelial Cells

C. Rousselle, S. Cisternino, J. Scherrmann, 2003, Pharmaceutical Research.

LC–MS/MS‐based quantification of efflux transporter proteins at the BBB

M. Picard, M. Vidal, I. Broutin, 2019, Journal of pharmaceutical and biomedical analysis.

Concepts for toxicokinetic-toxicodynamic modelling in clinical toxicology: application to acute cardiac glycoside intoxications.

M. Debray, J. Scherrmann, F. Baud, 1992, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

Relationship between red blood cell potassium and plasma digitoxin concentrations in intoxicated patients.

J. Scherrmann, C. Bismuth, M. Urtizberea, 1991, Pharmacology & toxicology.

Colchicine disposition in human leukocytes after single and multiple oral administration

P. Hung, E. Niel, J. Wautier, 1993, Clinical pharmacology and therapeutics.

The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats.

J. Wautier, M. Nagashima, J. Morser, 1999, The Journal of pharmacology and experimental therapeutics.

P‐glycoprotein (ABCB1) but not multidrug resistance‐associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes

X. Declèves, M. Tardy, J. Scherrmann, 2003, Journal of neurochemistry.

Screening of Multidrug-Resistance Sensitive Drugs by In Situ Brain Perfusion in P-Glycoprotein-Deficient Mice

C. Rousselle, S. Cisternino, J. Scherrmann, 2001, Pharmaceutical Research.

Monoclonal Antibodies in Hapten Immunoassays

O. Chappey, J. Scherrmann, P. Sandouk, 1992, Pharmaceutical Research.

Functional expression of p‐glycoprotein and multidrug resistance‐associated protein (mrp1) in primary cultures of rat astrocytes

J. Laplanche, J. Launay, X. Declèves, 2000, Journal of neuroscience research.

Effect of a Roux-en-Y Gastric Bypass on the Pharmacokinetics of Oral Morphine Using a Population Approach

J. Oppert, J. Bouillot, C. Poitou, 2014, Clinical Pharmacokinetics.

1-Methyl-4-phenylpyridinium (MPP+) does not exhibit paraquat-like immunoreactivity.

P. Houzé, O. Chappey, J. Scherrmann, 1990, Toxicology letters.

Elevated concentrations of morphine 6‐beta‐D‐glucuronide in brain extracellular fluid despite low blood–brain barrier permeability

J. Scherrmann, G. Boschi, P. Sandouk, 1999, British journal of pharmacology.

Hydroxychloroquine and Azithromycin to Treat Patients With COVID‐19: Both Friends and Foes?

B. Mégarbane, J. Scherrmann, 2020, Journal of clinical pharmacology.

Multidrug Resistance-Associated Protein MRP1 Expression in Human Gliomas: Chemosensitization to Vincristine and Etoposide by Indomethacin in Human Glioma Cell Lines Overexpressing MRP1

J. Bernaudin, K. Mokhtari, J. Delattre, 2004, Journal of Neuro-Oncology.

Changes in dipole membrane potential at the mouse blood–brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2

N. Rizzo-Padoin, A. Schinkel, S. Cisternino, 2009, Journal of neurochemistry.

ABC drug transporter and nuclear receptor expression in human cytotrophoblasts: influence of spontaneous syncytialization and induction by glucocorticoids.

F. Goffinet, H. Chappuy, X. Declèves, 2012, Placenta.

[Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier].

X. Declèves, J. Scherrmann, Aude Jacob, 2012, Biologie aujourd'hui.

Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes.

B. Weill, F. Batteux, S. Chouzenoux, 2010, International journal of pharmaceutics.

Evidence for an active transport of morphine‐6‐β‐d‐glucuronide but not P‐glycoprotein‐mediated at the blood–brain barrier

J. Temsamani, S. Cisternino, J. Scherrmann, 2003, Journal of neurochemistry.

Induction of P‐glycoprotein and Bcrp at the rat blood–brain barrier following a subchronic morphine treatment is mediated through NMDA/COX‐2 activation

X. Declèves, I. Margaill, J. Scherrmann, 2012, Journal of neurochemistry.

Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar

G. Camenisch, M. Lemaire, J. Scherrmann, 2007, Pharmaceutical Research.

Attention-Deficit and Disruptive Behavior Disorders

C. McDougle, D. Posey, C. Buhusi, 2014 .

Attention Deficit Hyperactivity Disorders: Animal Models

C. McDougle, D. Posey, C. Buhusi, 2014 .

Specific interaction between antidigoxin antibodies and digoxin-like immunoreactive substances in cord serum.

J. Scherrmann, X. Guédeney, P. Sandouk, 1986, Clinical chemistry.

Molecular and functional MDR1‐Pgp and MRPs expression in human glioblastoma multiforme cell lines

J. Laplanche, J. Bernaudin, I. Hurbain, 2002, International journal of cancer.

Effect of chronic exposure to morphine on the rat blood–brain barrier: focus on the P‐glycoprotein

X. Declèves, C. Marie-Claire, S. Cisternino, 2008, Journal of neurochemistry.

Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes

M. Alyanakian, P. Aucouturier, J. Scherrmann, 2003, Vox sanguinis.

Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells

F. Noble, C. Marie-Claire, J. Scherrmann, 2008, Neuropharmacology.

Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment.

B. Kommerell, I. Walter‐Sack, J. Scherrmann, 1994, Scandinavian journal of gastroenterology.

Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial

B. Mégarbane, J. Scherrmann, 2020, The Journal of antimicrobial chemotherapy.

Colchicine today.

E. Niel, J. Scherrmann, E. Niel, 2006, Joint, bone, spine : revue du rhumatisme.

DOSE-DEPENDENT EFFECTS ON VENTILATION AT REST INDUCED BY HIGH DOSES OF CANNABINOIDS IN RATS

P. Houzé, C. Pope, J. Scherrmann, 2010 .

Colchicine in breast milk of patients with familial Mediterranean fever.

E. Ben-Chetrit, M. Levy, J. Scherrmann, 1996, Arthritis and rheumatism.

Pharmacokinetics of colchicine: a review of experimental and clinical data.

J. Scherrmann, G. Achtert, M. Urtizberea, 1992, Zeitschrift fur Gastroenterologie.

Prognosis and treatment of paraquat poisoning: a review of 28 cases.

R. Garnier, J. Scherrmann, C. Bismuth, 1982, Journal of toxicology. Clinical toxicology.

Influence of goat colchicine specific antibodies on murine colchicine disposition.

J. Scherrmann, M. Urtizberea, N. Terrien, 1989, Toxicology.

Pharmacokinetics / bioavailability of colchicine in healthy male volunteers

J. Scherrmann, G. Achtert, M. Christen, 1989, European Journal of Drug Metabolism and Pharmacokinetics.

Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?

E. Niel, M. Debray, X. Declèves, 2006, Toxicology and applied pharmacology.

[Colchicine: recent data on pharmacokinetics and clinical pharmacology].

O. Chappey, J. Scherrmann, 1995, La Revue de medecine interne.

Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions.

J. Lang, J. Scherrmann, C. Lutsch, 1996, Toxicology and applied pharmacology.

Oral Absorption Characteristics and Pharmacokinetics of Colchicine in Healthy Volunteers after Single and Multiple Doses

W. Jusko, G. Ferron, J. Scherrmann, 1996, Journal of clinical pharmacology.

Covalent modifications of antitetanus F(ab')2 fragments with natural and synthetic polyamines and their effects on the antibody endocytosis in cultured HL60 cells.

P. Carrupt, J. Scherrmann, P. D'athis, 2008, Bioconjugate chemistry.

Stereoselectivity of Antibodies for the Bioanalysis of Chiral Drugs

P. Got, J. Scherrmann, 1997, Pharmaceutical Research.

Association constants of monoclonal antibodies for hapten: heterogeneity of frequency distribution and possible relationship with hapten molecular weight.

E. Niel, M. Debray, O. Chappey, 1994, Journal of immunological methods.

Improved Brain Delivery of Benzylpenicillin with a Peptide-vector-mediated Strategy

C. Rousselle, J. Temsamani, J. Scherrmann, 2002, Journal of drug targeting.

Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions

J. Scherrmann, C. Girre, N. Rizzo, 1996, European Journal of Clinical Pharmacology.

Digitalis-like factors and digoxin pharmacokinetics.

J. Scherrmann, X. Guédeney, P. Sandouk, 1986, Chest.

Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study

J. Scherrmann, H. Bhargava, M. Barjavel, 1995, British journal of pharmacology.

Dose-dependent reversal of digoxin-inhibited activity of an in vitro Na+K+ATPase model by digoxin-specific antibody.

M. Debray, J. Scherrmann, A. Sabouraud, 1996, Toxicology letters.

Affinity and dose-dependent digoxin Na+K+ATPase dissociation by monoclonal digoxin-specific antibodies.

I. Navarro-Teulon, M. Debray, J. Scherrmann, 1995, Biochemical pharmacology.

Design of Cocaethylene and Cocaine Conjugates to Produce Highly Selective Polyclonal Antibodies

H. Galons, J. Scherrmann, G. Folléa, 2006, International journal of biomedical science : IJBS.

Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line

B. Weill, C. Chéreau, F. Batteux, 2012, Journal of chemotherapy.

Production and characterization of polyclonal anti-S 20499 antibodies: influence of the hapten structure on stereospecificity.

C. Boursier-Neyret, P. Got, J. Scherrmann, 1997, Journal of pharmaceutical sciences.

In Situ Mouse Carotid Perfusion Model: Glucose and Cholesterol Transport in the Eye and Brain

S. Cisternino, J. Scherrmann, F. Bourasset, 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Transport of Biogenic Amine Neurotransmitters at the Mouse Blood–Retina and Blood–Brain Barriers by Uptake1 and Uptake2

A. Schinkel, C. Marie-Claire, S. Cisternino, 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Plasma and Cerebrospinal Fluid Concentrations of Morphine and Morphine Glucuronides after Oral Morphine: The Influence of Renal Failure

G. Dhonneur, P. Duvaldestin, A. Gilton, 1994, Anesthesiology.

Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis.

M. Plotkine, J. Scherrmann, M. Barjavel, 1994, Life sciences.

Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat.

J. Scherrmann, P. Sandouk, F. Stain‐Texier, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Blood–Brain Barrier

J. Scherrmann, 2014 .

Morphine pharmacokinetics in renal failure.

R. Farinotti, P. Duvaldestin, M. Chauvin, 1985 .

Markedly altered colchicine kinetics in a fatal intoxication: Examination of contributing factors

J. Scherrmann, F. Baud, S. Borron, 1996, Human & experimental toxicology.

Binding of colchicine and thiocolchicoside to human serum proteins and blood cells.

O. Chappey, J. Scherrmann, T. Dupin, 1994, International journal of clinical pharmacology and therapeutics.

Prognostic Value of Plasma and Urine Paraquat Concentration

P. Houzé, J. Scherrmann, R. Bourdon, 1987, Human toxicology.

Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier.

N. Rizzo-Padoin, X. Declèves, S. Cisternino, 2009, Journal of pharmaceutical sciences.

Sprague–Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)

H. Galons, M. Debray, X. Declèves, 2008 .

The Use of Antibodies As Therapeutic Agents in Toxicology

J. Scherrmann, F. Baud, C. Bismuth, 1997 .

A critical review of antidotal immunotherapy for low molecular weight toxins. Current antidotes and perspectives.

J. Scherrmann, F. Baud, S. Borron, 1997, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

Antibodies Proposed as Therapeutic Agents

J. Scherrmann, F. Baud, S. Borron, 1996 .

Pharmacokinetics of total and free digoxin and Fab fragments in 5 intoxicated patients after administration of specific anti-digoxin Fab fragments.

V. Cosson, O. Chappey, J. Scherrmann, 1991, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine.

J. Scherrmann, A. Sabouraud, M. Martinet, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Methodologies to Assess Drug Permeation Through the Blood–Brain Barrier for Pharmaceutical Research

P. Carrupt, S. Martel, J. Scherrmann, 2013, Pharmaceutical Research.

Influence of P-Glycoprotein Inhibition or Deficiency at the Blood–Brain Barrier on 18F-2-Fluoro-2-Deoxy-d-glucose (18F-FDG) Brain Kinetics

Philippe Gervais, H. Valette, M. Bottlaender, 2015, The AAPS Journal.

Morphine pharmacokinetics and pain assessment after intracerebroventricular administration in patients with terminal cancer

M. Debray, P. Got, J. Scherrmann, 1991, Clinical pharmacology and therapeutics.

Rate-limiting diffusion processes following intrathecal administration of morphine

M. Chauvin, J. Scherrmann, P. Sandouk, 1987, European Journal of Clinical Pharmacology.

A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

J. Goudemand, C. Négrier, H. Chambost, 1998, Thrombosis and Haemostasis.

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

P. Mannucci, A. Borel‐Derlon, J. Goudemand, 2005, Journal of thrombosis and haemostasis : JTH.

Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine.

J. Scherrmann, J. Bourre, A. Serrié, 1991, European journal of drug metabolism and pharmacokinetics.

Morphine Pharmacokinetics in Renal Failure

R. Farinotti, P. Duvaldestin, M. Chauvin, 1987, Anesthesiology.

Morphine disposition in opiate-intoxicated patients: relevance of nonspecific opiate immunoassays.

P. Got, J. Scherrmann, F. Baud, 1994, Journal of analytical toxicology.

Combined liquid-solid chromatography and radioimmunoassay for determination of morphine in human fluids.

J. Scherrmann, R. Bourdon, P. Sandouk, 1984, Journal of Pharmacological Methods.

Epidemiokinetic Tools to Monitor Lockdown Efficacy and Estimate the Duration Adequate to Control SARS-CoV-2 Spread

B. Mégarbane, J. Scherrmann, F. Bourasset, 2021, Journal of Epidemiology and Global Health.

Radioimmunoassay for colchicine: synthesis and properties of three haptens.

J. Scherrmann, R. Pontikis, L. Boudet, 1980, Journal of immunoassay.

Colchicine in Tear Fluid of Treated Patients With Familial Mediterranean Fever

A. Loewenstein, I. Barequet, T. O'brien, 2003, Cornea.

Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution.

C. Pham-Huy, J. Scherrmann, C. Girre, 1999, Journal of chromatography. B, Biomedical sciences and applications.

PRECLINICAL STUDY: Modulation of MDMA‐induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice

F. Noble, C. Marie-Claire, J. Scherrmann, 2009, Addiction biology.

New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

C. Rousselle, M. Kaczorek, J. Temsamani, 2000, Molecular pharmacology.

Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier

G. Camenisch, M. Lemaire, J. Scherrmann, 2006, Drug Metabolism and Disposition.

Doxorubicin-peptide conjugates overcome multidrug resistance

C. Rousselle, J. Temsamani, J. Scherrmann, 2001, Anti-cancer drugs.

Simultaneous microdialysis in brain and blood of the mouse: extracellular and intracellular brain colchicine disposition

J. Scherrmann, R. Verbeeck, Jean-Michel Scherrmann, 1998, Brain Research.

A sensitive radioimmunoassay for colchicine

J. Scherrmann, R. Pontikis, L. Boudet, 1980, The Journal of pharmacy and pharmacology.

Pharmacology of Morphine in Obese Patients

K. Clément, J. Lépine, J. Oppert, 2009, Clinical pharmacokinetics.

Hypoxia interferes with aryl hydrocarbon receptor pathway in hCMEC/D3 human cerebral microvascular endothelial cells

C. Peyssonnaux, X. Declèves, E. Curis, 2015, Journal of neurochemistry.

4-Methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients

J. Scherrmann, H. Faessel, P. Houzé, 2004, European Journal of Clinical Pharmacology.

Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments.

E. Vicaut, J. Lang, P. Taboulet, 1995, The New England journal of medicine.

Personality: Neurobehavioural Foundation and Pharmacological Protocols

Stephanie A. Carmack, C. McDougle, D. Posey, 2014 .

REGIOSELECTIVE HYDROLYSIS OF COCAINE AND A CONVENIENT ACYLATION PROCEDURE BY BENZOYLECGONINE

F. Martinet, H. Galons, J. Scherrmann, 1997 .

Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties

F. Noble, C. Marie-Claire, C. Courtin, 2014, Psychopharmacology.

Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-β peptide.

R. Farinotti, H. Chacun, C. Yapo, 2013, Journal of Alzheimer's disease : JAD.

A comparative study between animals and monoclonal anti-digitoxin antibodies.

J. Scherrmann, L. Edelman, A. Collignon, 1984, International journal of nuclear medicine and biology.

Endogenous digitalis-like immunoreactive substances in cord serum characterized by anti-digitoxin and anti-digoxin antibodies. Effect of modulated incubation conditions.

J. Scherrmann, X. Guédeney, P. Sandouk, 1986, Clinical biochemistry.

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats

S. Cisternino, J. Scherrmann, F. Bourasset, 2003, British journal of pharmacology.

Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients.

G. Ferron, M. Debray, J. Scherrmann, 1995, International journal of clinical pharmacology and therapeutics.

Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine.

S. Desrayaud, M. Lemaire, J. Scherrmann, 1997, Life sciences.

Pharmacokinetics of Unchanged Morphine in Normal and Cirrhotic Subjects

J. Mazoit, J. Scherrmann, P. Zetlaoui, 1987, Anesthesia and analgesia.

Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits.

C. Bon, F. Audebert, J. Scherrmann, 1994, The Journal of pharmacology and experimental therapeutics.

The Biology and Function of Transporters

J. Scherrmann, 2007 .

[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.

R. Boisgard, B. Hosten, F. Dollé, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacokinetic profiles of methadone enantiomers and its major metabolite in serum, saliva and urine of treated patients

C. Pham-Huy, H. Galons, J. Warnet, 1998 .

Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

François Bouzom, Bernard Walther, B. Walther, 2013, The AAPS Journal.

Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats

S. Ait-Oudhia, W. Krzyzanski, J. Scherrmann, 2010, Journal of Pharmacology and Experimental Therapeutics.

Time‐dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats

S. Ait-Oudhia, W. Krzyzanski, J. Scherrmann, 2010, Biopharmaceutics & drug disposition.

Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.

T. Terasaki, P. Couraud, S. Ohtsuki, 2013, Molecular pharmaceutics.

Transporters in Absorption, Distribution, and Elimination.

J. Scherrmann, 2010 .

Transporters in Absorption, Distribution, and Elimination

J. Scherrmann, 2009, Chemistry & biodiversity.

Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood–brain barrier in mice

B. Mégarbane, X. Declèves, J. Schlatter, 2012, Critical care medicine.

Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors

A. Rees, G. Drin, C. Rousselle, 2002, AAPS PharmSci.

The use of Pep: Trans vectors for the delivery of drugs into the central nervous system

J. Temsamani, J. Scherrmann, 2005 .

Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel

J. Temsamani, C. Bonnafous, S. Cisternino, 2004, Anti-cancer drugs.

P-Glycoprotein Is More Efficient at Limiting Uptake than Inducing Efflux of Colchicine and Vinblastine in HL-60 Cells

E. Niel, X. Declèves, O. Chappey, 1998, Pharmaceutical Research.

Peptide vectors as drug carriers.

J. Temsamani, J. Scherrmann, 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

Role of P‐170 glycoprotein in colchicine brain uptake

N. Cholet, J. Scherrmann, C. Chanez, 1997, Journal of neuroscience research.

Role of P-glycoprotein in colchicine and vinblastine cellular kinetics in an immortalized rat brain microvessel endothelial cell line.

M. Piciotti, F. Roux, J. Scherrmann, 1997, Biochemical pharmacology.

Role of P‐Glycoprotein in the Blood‐Brain Transport of Colchicine and Vinblastine

M. Lemaire, J. Scherrmann, J. Lefauconnier, 1996, Journal of neurochemistry.

Toxicokinetics of Paraquat in Humans

C Bismuth, P Houzé, F J Baud, 1990, Human & experimental toxicology.

Toxicokinetics of paraquat through the heart-lung block. Six cases of acute human poisoning.

J. Scherrmann, F. Baud, C. Bismuth, 1988, Journal of toxicology. Clinical toxicology.

Effects of nitrous oxide on dopamine release in the rat nucleus accumbens and expectation of reward

F. Noble, N. Benturquia, J. Scherrmann, 2008, Neuroscience.

Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).

H. Galons, M. Debray, X. Declèves, 2008, Toxicology and applied pharmacology.

Pharmacokinetics of Heterologous and Homologous Immunoglobulin G, F(ab‘)2 and Fab after Intravenous Administration in the Rat

J. Scherrmann, MARTINE I. BAZIN‐REDUREAU, CATHERINE B. RENARD, 1997, The Journal of pharmacy and pharmacology.

Hepatic disposition and toxicity of cationized goat immunoglobulin G and fab fragments in isolated perfused rat liver.

J. Scherrmann, G. Hong, M. Bazin-Redureau, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Enhanced Cellular Uptake and Transport of Polyclonal Immunoglobulin G and Fab After Their Cationization

O. Chappey, J. Scherrmann, G. Hong, 2000, Journal of drug targeting (Print).

Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat.

J. Scherrmann, G. Hong, M. Bazin-Redureau, 1999, Journal of pharmaceutical sciences.

Immunoglobulin G, F(AB')2, and fab fragment uptake kinetics in isolated perfused rat liver and rat hepatic cells.

J. Scherrmann, M. Bazin-Redureau, P. Chapelle, 1995, Drug Metabolism And Disposition.

ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.

M. Debray, X. Declèves, G. Camenisch, 2008, Pharmacological research.

Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood–brain barrier

G. Camenisch, M. Lemaire, J. Scherrmann, 2007, Journal of neurochemistry.

CNS Delivery Via Adsorptive Transcytosis

J. Scherrmann, N. Ghinea, F. Hervé, 2008, The AAPS Journal.

Development and validation of an antigen-binding capture ELISA for native and putrescine-modified anti-tetanus F(ab')2 fragments for the assessment of the cellular uptake and plasma kinetics of the antibodies.

J. Scherrmann, P. D'athis, F. Hervé, 2005, Journal of immunological methods.

Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats.

A. Schmidt, J. Wautier, M. Nagashima, 1997, Molecular pharmacology.

ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier

C. Daumas-Duport, R. Weaver, I. de Waziers, 2008, Journal of neurochemistry.

Radioimmunoassay of Colchicine with Antisera Exhibiting Variable Cross‐Reactivity

J. Scherrmann, A. Sabouraud, N. Cano, 1994, Therapeutic drug monitoring.

Pharmacokinetics and absolute bioavailability of colchicine after i. v. and oral administration in healthy human volunteers and elderly subjects

J. Scherrmann, C. Girre, A. Sabouraud, 2004, European Journal of Clinical Pharmacology.

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

D. Mager, M. Chenel, G. Chichili, 2018, Clinical Cancer Research.

Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells.

R. Weaver, I. de Waziers, P. Couraud, 2009, Biochemical pharmacology.

Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.

J. Lépine, J. Laplanche, P. Houzé, 2015, British journal of clinical pharmacology.

Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy

A. Rees, C. Rousselle, M. Kaczorek, 2005, Journal of Pharmacology and Experimental Therapeutics.

Cyclosporin Absorption Is Impaired by the Fat Substitutes, Sucrose Polyester and Tricarballylate Triester, in the Rat

J. Scherrmann, J. Bourre, A. Sabouraud, 1994, Pharmaceutical Research.

Effect of Fat Substitutes, Sucrose Polyester and Tricarballylate Triester, on Digitoxin Absorption in the Rat

D. Brossard, J. Scherrmann, J. Bourre, 1993, The Journal of pharmacy and pharmacology.

Human monoclonal anti‐D with a normal half‐life

J. Scherrmann, Marcela Contreras, Therese A. Callaghan, 1993, Transfusion.

Inhibition of colchicine absorption by the fat substitutes, sucrose polyester and tricarballylate triester, in the rat.

J. Scherrmann, J. Bourre, K. Benmoussa, 1995, Life sciences.

A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood‐retinal barrier

X. Declèves, S. Cisternino, J. Scherrmann, 2015, British journal of pharmacology.

MODEL‐INDEPENDENT PHARMACOKINETICS OF COLCHICINE AFTER ORAL ADMINISTRATION TO HEALTHY VOLUNTEERS

J. Scherrmann, C. Girre, P. Fournier, 1989, Fundamental & clinical pharmacology.

Colchicine disposition in patients with familial Mediterranean fever with renal impairment.

E. Ben-Chetrit, M. Levy, J. Scherrmann, 1994, The Journal of rheumatology.

Colchicine concentration in leukocytes of patients with familial Mediterranean fever.

E. Niel, O. Chappey, J. Scherrmann, 1994, British journal of clinical pharmacology.

Effect of social isolation on the metabolism of morphine and its passage through the blood-brain barrier and on consumption of sucrose solutions

M. Debray, J. Scherrmann, J. Bourre, 1999, Psychopharmacology.

Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

F. Calon, R. Farinotti, Wael Alata, 2015, Journal of Alzheimer's disease : JAD.

Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease

F. Calon, R. Farinotti, L. Pradier, 2014, Neuropharmacology.

Temperature-dependent immunoreactive assay to screen for digoxin-like immunoreactive factor(s).

J. Scherrmann, C. Chanez, X. Guédeney, 1991, Clinical Chemistry.

Drug delivery to brain via the blood-brain barrier.

J M Scherrmann, J. Scherrmann, 2002, Vascular pharmacology.

Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening

Nicolas Tournier, Bertrand Kuhnast, Michel Bottlaender, 2011, The Journal of Nuclear Medicine.

Snake F(ab′)2 Antivenom from Hyperimmunized Horse: Pharmacokinetics Following Intravenous and Intramuscular Administrations in Rabbits

J. Scherrmann, C. Lutsch, M. Grandgeorge, 1995, Pharmaceutical Research.

Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom.

J. Lang, J. Scherrmann, C. Lutsch, 1998, Journal of pharmaceutical sciences.

Blood–brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P‐glycoprotein on a novel verapamil influx carrier

F. Behar-Cohen, X. Declèves, S. Cisternino, 2016, British journal of pharmacology.

Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

Nicolas Tournier, Bruno Megarbane, B. Mégarbane, 2010, The international journal of neuropsychopharmacology.

Is Curfew Effective in Limiting SARS-CoV-2 Progression? An Evaluation in France Based on Epidemiokinetic Analyses

B. Mégarbane, J. Scherrmann, F. Bourasset, 2021, Journal of General Internal Medicine.

Is Lockdown Effective in Limiting SARS-CoV-2 Epidemic Progression?—a Cross-Country Comparative Evaluation Using Epidemiokinetic Tools

B. Mégarbane, J. Scherrmann, F. Bourasset, 2021, Journal of General Internal Medicine.

Functional and targeted proteomics characterization of a human primary endothelial cell model of the blood-brain barrier (BBB) for drug permeability studies.

X. Declèves, A. Moreau, S. Cisternino, 2023, Toxicology and applied pharmacology.

Pharmacophore‐based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line

P. Carrupt, L. Goracci, G. Cruciani, 2015, British journal of pharmacology.

Coexistence of Passive and Proton Antiporter-Mediated Processes in Nicotine Transport at the Mouse Blood–Brain Barrier

M. Debray, S. Cisternino, J. Scherrmann, 2013, The AAPS Journal.

Study of uranium transfer across the blood-brain barrier.

C. Rousselle, J. Scherrmann, E. Ansoborlo, 2003, Radiation protection dosimetry.

Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).

M. Debray, X. Declèves, F. Noble, 2009, Toxicology and applied pharmacology.

Heterogeneity in the Rat Brain Vasculature Revealed by Quantitative Confocal Analysis of Endothelial Barrier Antigen and P-Glycoprotein Expression

S. Cisternino, J. Scherrmann, B. Saubaméa, 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Detection and quantitation of cannabinoids in biological fluids: specificity and kinetics after smoking.

J. Scherrmann, J. Pichon, L. Boudet, 1981, Clinical toxicology.

Highly Specific Radioimmunoassay for Digoxin Using a Monoclonal Antibody Selected for Lack of Interference by Digoxin‐Like Immunoreactive Substances in Cord Blood Sera

B. Pau, J. Bastide, J. Grenier, 1991, Therapeutic Drug Monitoring.

Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide

Shailendra B. Patel, X. Declèves, Nathalie Prince, 2017, Scientific Reports.

ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.

F. Calon, R. Farinotti, M. Buyse, 2012, Journal of Alzheimer's disease : JAD.

Aryl hydrocarbon receptor regulates CYP1B1 but not ABCB1 and ABCG2 in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure

P. Couraud, X. Declèves, J. Scherrmann, 2015, Brain Research.

Carrier-Mediated Cocaine Transport at the Blood-Brain Barrier as a Putative Mechanism in Addiction Liability

P. Couraud, X. Declèves, J. Schlatter, 2014, The international journal of neuropsychopharmacology.

Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates

F. Dollé, H. Valette, M. Bottlaender, 2012, Pharmaceutical Research.

Population pharmacokinetics of 3,4-methylenedioxymethamphetamine and main metabolites in rats.

M. Debray, X. Declèves, F. Noble, 2010, Toxicological sciences : an official journal of the Society of Toxicology.

In Vivo Spectrophotometric Determination of Striatal Acetylcholinesterase Activity: The Modulation Induced by the Antidepressant Amitriptyline

J. Scherrmann, P. Gourmelon, Marc Fatome, 1990, Journal of neurochemistry.

Pharmacokinetics of Thiocolchicoside in Humans Using a Specific Radioimmunoassay

M. d’Yvoire, O. Chappey, J. Scherrmann, 1995, Therapeutic drug monitoring.

Extrahepatic metabolism of morphine occurs in humans

A. Roche, J. Mazoit, J. Scherrmann, 1990 .

NEUROPHARMACOKINETICS OF A NEW α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID (AMPA) MODULATOR, S18986 [(S)-2,3-DIHYDRO-[3,4]CYCLOPENTANO-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE], IN THE RAT

K. Bernard, J. Scherrmann, F. Bourasset, 2005, Drug Metabolism and Disposition.

Time course of antidigoxin fab Fragment and plasma digitoxin concentrations in an acute digitalis intoxication.

P. Pontal, T. Smith, J. Scherrmann, 1982, Journal of toxicology. Clinical toxicology.

Brain Distribution of Drugs: Brain Morphology, Delivery Routes, and Species Differences.

R. Thorne, J. Scherrmann, F. Bourasset, 2021, Handbook of experimental pharmacology.

Simple, rapid method for extraction of urinary cannabinoids by liquid-solid chromatography.

J. Scherrmann, M. Sonnier, H. Hoellinger, 1980, Journal of chromatography.

Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice

Christophe Rousselle, Gary M. Pollack, C. Rousselle, 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties

F. Noble, C. Marie-Claire, C. Courtin, 2014, Psychopharmacology.

Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology.

X. Declèves, S. Cisternino, N. Tournier, 2011, Current pharmaceutical design.

Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis againstPlasmodium falciparum malaria

J. Bras, E. Pussard, M. Blayo, 2004, European Journal of Clinical Pharmacology.

Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.

J. Oppert, T. Terasaki, J. Bouillot, 2016, Molecular pharmaceutics.

Effects of Selected OATP and/or ABC Transporter Inhibitors on the Brain and Whole-Body Distribution of Glyburide

F. Dollé, H. Valette, A. Dubois, 2013, AAPS Journal.

Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels

X. Coumoul, X. Declèves, J. Scherrmann, 2011, Fluids and Barriers of the CNS.

Immunoreactivity of a new generation of horse F(ab')2 preparations against European viper venoms and the tetanus toxin.

J. Scherrmann, C. Lutsch, M. Grandgeorge, 1997, Toxicon : official journal of the International Society on Toxinology.

Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide

X. Declèves, Nathalie Prince, M. Wortman, 2017, Scientific Reports.

How to obtain DNA from injection drug users?

J. Lépine, J. Laplanche, X. Declèves, 2011, Clinical chemistry and laboratory medicine.

[Combined ursodeoxycholic acid plus colchicine--treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study].

B. Kommerell, J. Scherrmann, R. Raedsch, 1992, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

Facilitation of imipramine efflux from the brain by systemic specific antibodies

J. Scherrmann, G. Boschi, R. Rips, 1996, British journal of pharmacology.

Single‐dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers

P. Chrétien, J. Tillement, M. d’Yvoire, 1994, Biopharmaceutics & drug disposition.

Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

B. Walther, X. Declèves, J. Scherrmann, 2013, The AAPS Journal.

Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone.

B. Walther, X. Declèves, J. Scherrmann, 2012, Journal of pharmaceutical sciences.

Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide.

J. Scherrmann, F. Bourasset, 2006, Life sciences.

Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID‐19 Therapy

J. Scherrmann, 2020, Clinical pharmacology and therapy.

Extrahepatic metabolism of morphine occurs in humans.

A. Roche, J. Mazoit, J. Scherrmann, 1988, Clinical pharmacology and therapeutics.

[Cationization, a process for the delivery of antibodies to the central nervous system. Problems encountered in its application for immunotherapy strategies such as those for clostridial poisoning].

J. Scherrmann, F. Hervé, J. Ouzilou-Girod, 2001, Journal de la Société de Biologie.

Effect of Long-term In Vitro Lithium Exposure on mRNA Levels of Claudin-3, CYP1A1, ABCG2 and GSTM3 Genes in the hCMEC/D3 Human Brain Endothelial Cell Line

P. Couraud, R. Shawahna, X. Declèves, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

[Prognostic factors in acute digitalis poisoning].

A. Alpérovitch, G. Lagier, J. Scherrmann, 1982, Schweizerische medizinische Wochenschrift.

Patient-controlled analgesia.

B. J. Harrison, Stephanie A. Carmack, John F. G. Atack, 1986, Nursing.

Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration.

R. Shawahna, X. Declèves, J. Scherrmann, 2014, Current pharmaceutical design.

Determination of 3,4-methylenedioxymethamphetamine and its five main metabolites in rat urine by solid-phase extraction and high performance liquid chromatography with on line mass spectrometry.

F. Noble, J. Scherrmann, M. Menet, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients.

J. Soulillou, Y. Le Meur, M. Debray, 1996, Kidney international. Supplement.

Antibodies proposed as therapeutic agents.

J. Scherrmann, F. Baud, S. Borron, 1995, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier

U. Tröger, C. Wallesch, S. Bode-Böger, 2005, BMJ : British Medical Journal.

Applications of a Blood-Brain Barrier Technology Platform to Predict CNS Penetration of Various Chemotherapeutic Agents. 2. Cationic Peptide Vectors for Brain Delivery

J. Scherrmann, N. Perrière, M. Adenot, 2007, Chemotherapy.

Influence of P-Glycoprotein Inhibition or Deficiency at the Blood–Brain Barrier on 18F-2-Fluoro-2-Deoxy-d-glucose (18F-FDG) Brain Kinetics

H. Valette, M. Bottlaender, S. Goutal, 2015, The AAPS Journal.

Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

B. Mégarbane, X. Declèves, J. Scherrmann, 2010, The international journal of neuropsychopharmacology.

Dose-dependent delivery of colchicine to the rat hippocampus by microdialysis

S. Desrayaud, J. Scherrmann, G. Boschi, 1996, Neuroscience Letters.

Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.

Thierry Lavé, Christoph Funk, Agnès Poirier, 2009, Molecular pharmaceutics.

Posttranslational Protein Modification

Stephanie A. Carmack, John F. G. Atack, C. McDougle, 2021, Encyclopedia of Molecular Pharmacology.

PRECLINICAL STUDY: Modulation of MDMA‐induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice

F. Noble, C. Marie-Claire, J. Scherrmann, 2009, Addiction biology.

Toxicokinetic-toxicodynamic models describing the relation of plasma and red blood cell potassium with plasma digitalis in acute human digitalis poisoning.

J. Scherrmann, F. Baud, M. Urtizberea, 1990, Toxicology in vitro : an international journal published in association with BIBRA.

Cross reactivity of digitoxin in radioimmunoassay and enzyme-linked immunoassay for digoxin in plasma.

J. Scherrmann, R. Bourdon, 1980, Clinical Chemistry.

Zero-order absorption and linear disposition of oral colchicine in healthy volunteers

J. Steimer, P. Francheteau, J. Scherrmann, 2004, European Journal of Clinical Pharmacology.

Pharmacokinetics and absolute bioavailability of colchicine after i. v. and oral administration in healthy human volunteers and elderly subjects

J. Scherrmann, C. Girre, A. Sabouraud, 2004, European Journal of Clinical Pharmacology.

Monoclonal Digoxin-Specific Antibodies Induce Dose-and Affinity-Dependent Plasma Digoxin Redistribution in Rats

F. Roquet, I. Navarro-Teulon, J. Scherrmann, 1995, Pharmaceutical Research.

Clonidine Transport at the Mouse Blood—Brain Barrier by a New H+ Antiporter that Interacts with Addictive Drugs

M. Debray, S. Cisternino, J. Scherrmann, 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.